{"id":237303,"date":"2026-09-09T12:22:24","date_gmt":"2026-09-09T06:52:24","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=237303"},"modified":"2026-09-09T12:22:24","modified_gmt":"2026-09-09T06:52:24","slug":"is-bal-pharma-a-good-buy-after-q1-fy27-results","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/is-bal-pharma-a-good-buy-after-q1-fy27-results\/","title":{"rendered":"Is Bal Pharma a Good Buy After Its Q1 FY27 Results?"},"content":{"rendered":"

Bal Pharma share price around Rs 114. 0.0% below 52-week high of Rs 114. Q1 FY27 revenue Rs 89 crore, up 33.7% YoY. PAT Rs 1.14 crore, up 442.9%. PE 21x.<\/em><\/p>\n

\n

Quick Answer<\/strong><\/p>\n

Bal Pharma’s Q1 FY27 results were strong, with revenue at Rs 89 crore and PAT climbing 443% to Rs 1.14 crore. Note that the year-ago quarter’s profit base was unusually low, which inflates the headline growth rate. The stock trades at a PE of 21x against an industry average near 38x, which leaves room for a re-rating if this growth continues. The Bal Pharma share price near Rs 114 reflects that optimism, so investors weighing whether Bal Pharma is a good buy today should focus on whether this pace of growth can be sustained rather than just this quarter’s print.<\/p>\n<\/p><\/div>\n

The Bal Pharma share price has been under the spotlight this results season after the company reported its first-quarter numbers for FY27. Bal Pharma is a manufacturer of pharmaceutical formulations and active pharmaceutical ingredients, and its Q1 FY27 print, for the quarter ended June 30, 2026, gives investors a fresh data point to test whether the stock still deserves a place in a portfolio at current levels.<\/p>\n

Revenue for the quarter came in at Rs 89 crore, up 33.7% year on year, while profit after tax came in at Rs 1.14 crore, up 442.9% from a year earlier. That combination of numbers is exactly what this article breaks down, along with what it means for the Bal Pharma share price from here.<\/p>\n

This piece works through the quarter’s financial highlights, the business factors behind the numbers, where the Bal Pharma share price stands against its 52-week range and valuation multiples, and the key risks worth watching before treating this as a buy, hold or a stock to avoid for now.<\/p>\n

Click Here – Get Free Investment Predictions<\/strong><\/a><\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n